Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.
トレード
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Tape desk, TradeNews BD (2026-09-30): Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. 一次ソース: Nasdaq Market Structure の原文 (nasdaq.com).